psoriasis
Boehringer Ingelheim’s Spevigo gains additional approvals in US and China
March 20, 2024Medical Communications Boehringer Ingelheim, Dermatology, FDA, Spevigo, psoriasis
Boehringer Ingelheim has announced that Spevigo (spesolimab-sbzo) has been approved by the US Food and Drug Administration (FDA) for the …
Bristol Myers Squibb’s Sotyktu recommended for NHS use for adult patients with psoriasis
June 28, 2023Medical Communications Dermatology, NHS, Sotyktu, bristol myers squibb, psoriasis
Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence (NICE) has recommended Sotyktu (deucravacitinib) …
Bristol Myers Squibb psoriasis drug shows positive Phase III results
April 29, 2021Bristol-Myers Squibb, bristol myers squibb, pharma, pharma news, psoriasis, psoriasis treatment
Bristol Myers Squibb’s investigational deucravacitinib drug, for the treatment of moderate-to-severe plaque psoriasis, has shown positive results in two Phase …
Lipidor to begin Phase III trial on psoriasis treatment
April 22, 2021Phase III trials, lipidor, pharma, pharma news, psoriasis
Lipidor has submitted an application with the Indian Medical Products Agency to begin a Phase III trial on their drug …
Dermavant announces positive Phase III findings for psoriasis treatment tapinarof
February 19, 2021Medical Communications Dermavant Sciences, psoriasis
Dermavant Sciences has announced positive safety and efficacy results from a planned interim analysis of PSOARING 3, a long-term, open-label …
MC2 Therapeutics grants Almirall European commercial rights for psoriasis cream Wynzora
February 18, 2021Almirall, MC2 Therapeutics, psoriasis
Biopharma company Almirall and MC2 Therapeutics, a pharmaceutical company focused on therapies for autoimmune and chronic inflammatory conditions, have announced …
Novartis’ Cosentyx gets European go-ahead in paediatric plaque psoriasis
August 3, 2020Sales and Marketing Cosentyx, Europe, Novartis, pharma, psoriasis
Novartis’ interleukin-17A (IL-17A) inhibitor Cosentyx (secukinumab) has chalked up approval from the European Commission (EC) for the treatment of patients …
UCB’s investigational IL-17A and IL-17F inhibitor outclasses Novartis’ Cosentyx in plaque psoriasis
July 24, 2020Medical Communications, Research and Development Cosentyx, UCB, pharma, psoriasis
UCB has revealed promising new data from a head-to-head trial pitting the company’s IL-17A and IL-17F inhibitor bimekizumab against Novartis’ …
AbbVie’s Skyrizi outpaces Novartis’ Cosentyx in plaque psoriasis skin clearance
January 16, 2020Research and Development AbbVie, Cosentyx, Novartis, Skyrizi, pharma, psoriasis
AbbVie has made it known that Skyrizi (risankizumab) outpaced Novartis’ Cosentyx (secukinumab) at Phase 3 in the treatment of plaque …
Lilly’s Taltz beats Janssen’s Tremfya at Phase 4 in plaque psoriasis
August 15, 2019Research and Development Eli Lilly, Taltz, Tremfya, pharma, psoriasis
Eli Lilly has unveiled new Phase 4 data supporting the efficacy and safety of Taltz (ixekizumab) when compared to Janssen’s …
Novartis provides promising update on Cosentyx in plaque psoriasis
June 26, 2019Research and Development Cosentyx, Novartis, pharma, psoriasis
Novartis has revealed brief new data on its IL-17A antibody Cosentyx (secukinumab) in the treatment off plaque psoriasis, showing that …
Bristol-Myers Squibb to sell off Celgene’s Otezla ahead of $74 billion merger
June 24, 2019Manufacturing and Production Bristol-Myers Squibb, Celgene, FTC, otezla, pharma, psoriasis
Bristol-Myers Squibb has agreed to sell off Celgene’s psoriasis treatment Otezla, to appease antitrust regulators. BMS will divest one of …
New Phase 3 data confirms safety and efficacy of UCB’s Cimzia in plaque and psoriatic arthritis
April 30, 2019Manufacturing and Production, Research and Development Cimzia, UCB Pharma, pharma, plaque psoriasis, psoriasis
New Phase 3 data has been released by UCB Pharma on the safety of Cimzia (certolizumab pegol) in the treatment …
AbbVie’s Skyrizi snatches up FDA approval in moderate to severe plaque psoriasis
April 24, 2019Research and Development, Sales and Marketing AbbVie, FDA, Skyrizi, US, pharma, psoriasis
AbbVie has revealed that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab-rzaa) has received marketing authorisation in the US from the FDA …
NICE recommends UCB’s Cimzia in severe plaque psoriasis
April 18, 2019Sales and Marketing Cimzia, NICE, UCB Pharma, UK, pharma, plaque psoriasis, psoriasis
NICE has announced its decision to recommend UCB Pharma’s Cimzia (certolizumab pegol) for use on the NHS in England in …
Latest content
FibroFind appoints Lee Borthwick as CEO
